Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma
Authors:
- Victor G. PrietoVPVictor G. Prieto
- Matthew T. BalloMBMatthew T. Ballo
- Marcella M. JohnsonMJMarcella M. Johnson
- Janice N. CormierJCJanice N. Cormier
- Jeffrey E. GershenwaldJGJeffrey E. Gershenwald
Open Access
Abstract
BACKGROUND: The role of sentinel lymph node biopsy (SLNB) in the treatment of desmoplastic melanoma (DM) remains undefined. The purpose of this study was to evaluate the use of SLNB for DM.METHODS: In all, 1850 patients with cutaneous melanoma underwent wide local excision and SLNB. Patients with DM were identified and stratified as ‘pure’ DM or ‘mixed’ DM (i.e., DM associated with at least one other common histologic subtype).RESULTS: Of the 1850 patients, 65 (3.5%) had DM. Of these, 46 (70.8%) had pure DM and 19 (29.2%) had mixed DM. Patients with pure DM had a median tumor thickness of 3.5 mm and 6.5% were ulcerated. Compared with patients with pure DM, patients with either mixed DM or non‐DM (n = 1785) had thinner primary tumors (median, 1.7 mm and 1.5 mm, respectively, each P < 0.001 vs. pure DM) that were more likely to be ulcerated (27.7% and 21.3%, respectively, each P < 0.05 vs. pure DM). Although the incidence of a positive SLN was similar in patients with mixed DM (15.8%) and non‐DM (17.5%), patients with pure DM were less likely to have a positive SLN (2.2%) (each P < 0.01 vs. non‐DM and mixed DM). At a median follow‐up of 2.9 years, no patient with pure DM had recurred.CONCLUSIONS: Despite having thicker primary tumors, patients with pure DM have a lower incidence of positive SLNs compared with patients with non‐DM. Whereas the treatment approach for patients with mixed DM should be similar to that of other melanoma patients, patients with pure DM are unlikely to have metastatic disease in regional lymph nodes and SLNB may not be warranted. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 39 references indexed in Scilit:
- Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as ?Pure? or ?Mixed? May Have Important Prognostic SignificanceAnnals of Surgical Oncology, 2005
- Lymphatic Mapping in the Molecular EraAnnals of Surgical Oncology, 2004
- Gene Expression Profiling Of Human Cutaneous Melanoma: Are We There Yet?Cancer Biology & Therapy, 2004
- Efficacy of radiation therapy in the local control of desmoplastic malignant melanomaHead & Neck, 2003
- Desmoplastic neurotropic melanoma of the head and neck: The role of radiation therapyHead & Neck, 2002
- Desmoplastic malignant melanomaJournal of the American Academy of Dermatology, 1995
- Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 casesCancer, 1995
- Desmoplastic malignant melanoma: Rare and difficult to diagnoseJournal of the American Academy of Dermatology, 1992
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Desmoplastic melanoma: Patterns of recurrenceWorld Journal of Surgery, 1992